Jerusalem-based venture capital firm, Champel Capital, announced the first closing of its second fund, Champel Capital Impact Deep Tech Fund.
The fund will exclusively focus on Israeli deep tech startups in Series A phases specifically in the fields of agrifood, bioconvergence, industry 4.0, mobility, and fintech, the company said.
The VC made its first closing at $30 million.
Champel Capital will incorporate 15-20 portfolio companies that meet stringent criteria for impact investing, such as those that address some of the UN’s 17 sustainable development goals for 2030.
Past investments of Champel Capital include Aleph Farms, which developed a 3D tissue engineering platform to grow slaughter-free cultivated steaks directly from cow cell cultures; BodyVision, a cutting-edge lung cancer diagnostic and treatment platform; and Lemonade—the world’s first open-source insurance policy.
Founded in 2017, Champel Capital is led by Amir Weitmann and Arié Benguigui, managing partners who prioritize investment in the areas of the Israeli startup ecosystem that generate impact strategies towards positive, practical, and long-term sustainable solutions.
“As a young and dynamic company with a spirit of entrepreneurship, we look first and foremost at the vision leading the entrepreneur,” said Weitmann. “We believe that we should be investing in people, first and foremost. We strive to invest in companies led by great entrepreneurs capable of envisioning and growing great companies with products and/or services meeting real market needs in large and growing markets. We are very excited with our first closing and that we are now open for business.”